

% ======================================================================
% == Appendices for Chapter 1
% ======================================================================

\section{Chapter 1 Supplementary}
\label{apdx:supplemental}


% == Figures and Tables ================================================
\subsection{Figures \& Tables}
\label{subapdx:figtabs}
\newpage



% % ## Tab S1


{
    \footnotesize
    \newcommand{\myheader}{
        \hline
        \textbf{Cell Type} & \textbf{Donor / Line} & \textbf{Donor Ages} & \textbf{Donor Sex} & \textbf{Date of negative Mycoplasma test} & \textbf{Experiment(s)}                                                                                   & \textbf{Figures}                        \\
        \hline

    }
    \begin{longtable}{|>{\bfseries}p{1.5cm}|>{\bfseries}p{1.2cm}|p{1cm}|p{1cm}|p{2.3cm}|p{6cm}|p{1.7cm}|}
        \caption{%
            lorem ipsum dolor sit amet consectetur adipiscing elit sed do
            eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
            veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
            commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
            esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
        }\label{tab:S1}
        \\
        \myheader
        \endfirsthead

        \multicolumn{7}{c}%
        {Appendix \thesection~\tablename\ \thetable\ -- \textit{Continued from previous page}}                                                                                                               \\
        \myheader
        \endhead

        \hline
        \multicolumn{7}{r}{\textit{Continued on next page}}                                                                                                                                                  \\
        \endfoot

        \endlastfoot

        Myeloma Cell Line & INA-6 & 80 & m & 09.02.22   & All                                                                                                      & All                                     \\
        \hhline{~------}
                          & U266  &    &   & 10.10.22   & - Validation of V-Well Adhesion Assay                                                                    & S1E                                     \\
        \hhline{~----~~}
                          & MM1.S &    &   & 24.02.22   &                                                                                                          &                                         \\
        \hline
        hMSC              & 1639  & 49 & m & not tested & - Validation of V-Well Adhesion Assay                                                                    & S1E                                     \\
        \hhline{~~~~~--}
                          &       &    &   &            & - Time-lapse: INA-6 on dispersed hMSC                                                                    & 1D; 2[A-E]                              \\
        \hhline{~------}
                          & 1571  & 72 & m & not tested & - Saturation of hMSCs                                                                                    & 1[A-B]                                  \\
        \hhline{~----~~}
                          & 1573  & 47 & m & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1578  & 82 & m & not tested &                                                                                                          &                                         \\
        \hhline{~------}
                          & 1842  & 63 & m & not tested & - INA-6 Viability dependent on time and hMSC adhesion surface (INA not washed off)                       & 1E right                                \\
        \hhline{~----~~}
                          & 1843  & 60 & m & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1537  & 77 & f & not tested &                                                                                                          &                                         \\
        \hhline{~------}
                          & 1794  & 82 & m & not tested & - INA-6 Viability dependent on time and hMSC adhesion surface (INA washed off)                           & 1[C, E left]                            \\
        \hhline{~----~~}
                          & 1779  & 61 & m & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1849  & 69 & m & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1854  & 80 & f & not tested &                                                                                                          &                                         \\
        \hhline{~------}
                          & 1605  & 71 & f & not tested & - Time-lapse: INA-6 on dispersed hMSC                                                                    & 1D; 2[A-E]                              \\
        \hhline{~----~~}
                          & 1650  & 57 & m & not tested &                                                                                                          &                                         \\
        \hhline{~------}
                          & 1859  & 64 & f & not tested & - Time-lapse: INA-6 on confluent hMSC                                                                    & 2[G-I]                                  \\
        \hhline{~----~~}
                          & 1863  & 79 & f & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1861  & 52 & f & not tested &                                                                                                          &                                         \\
        \hhline{~------}
                          & 1818  & 81 & f & not tested & - Cell Cycle Profiling after V-well assay                                                                & 3C                                      \\
        \hhline{~------}
                          & 1824  & 82 & f & not tested & (Donor measured twice, different passages)                                                               & 3[B,C]                                  \\
                          &       &    &   &            & - V-well adhesion assay of mitotically blocked INA-6 followed by Cell Cycle Profiling after V-well assay &                                         \\
        \hhline{~----~~}
                          & 1827  & 56 & m & not tested & - V-well adhesion assay of mitotically blocked INA-6 followed by Cell Cycle Profiling after V-well assay & 3[B,C]                                  \\
        \hhline{~------}
                          & 1501  & 59 & m & not tested & - INA-6 AI-assisted count during WPSC (INA-6 stained with celltracker green)                             & 4B                                      \\
        \hhline{~----~~}
                          & 1643  & 75 & f & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1718  & 67 & m & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1720  & 58 & m & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1653  & 65 & m & not tested &                                                                                                          &                                         \\
        \hhline{~------}
                          & 1591  & 78 & m & not tested & - WPSC (MACS) followed by RNAseq, Metascape analysis, and qPCR validation                                & 4[A,C,D,E]; 5[A-C]                      \\
        \hhline{~~~~~--}
                          &       &    &   &            & - WPSC (Wash) followed by qPCR-Validation and Luminescent Viability assays                               & 4[C-E], 4F                              \\
        \hhline{~------}
                          & 1654  & 74 & m & not tested & - WPSC (MACS) followed by RNAseq, Metascape analysis, and qPCR validation                                & 4[A,C,D,E]; 5[A-C]                      \\
        \hhline{~~~~~--}
                          &       &    &   &            & - WPSC (Wash) followed by qPCR-Validation and Luminescent Viability assays                               & 4[C-E], 4F                              \\
        \hhline{~------}
        % Rows for Donor 1655, 1668, 1670 with shared experiment and figure cells
                          & 1655  & 78 & f & not tested & \multirow{3}{6cm}{- WPSC (MACS) followed by RNAseq, Metascape analysis, and qPCR validation}             & \multirow{3}{1.7cm}{4[A,C,D,E]; 5[A-C]} \\
        \hhline{~----~~}
                          & 1668  & 80 & f & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1670  & 66 & f & not tested &                                                                                                          &                                         \\
        \hhline{~------}
        % Rows with shared experiment and figure cells
                          & 1701  & 81 & m & not tested & \multirow{3}{6cm}{- WPSC (Wash) followed by qPCR-Validation and Luminescent Viability assays}            & \multirow{3}{1.7cm}{4[C-E], 4F}         \\
        \hhline{~----~~}
                          & 1702  & 79 & f & not tested &                                                                                                          &                                         \\
        \hhline{~----~~}
                          & 1600  & 77 & m & not tested &                                                                                                          &                                         \\
        \hhline{~------}

        % Row 37-39
                          & 1681  & 56 & m & not tested & - WPSC (Wash) followed by Luminescent Viability assays                                                   & 4F                                      \\
        \hhline{~------}
                          & 1672  & 65 & m & not tested & - WPSC (Wash) followed by qPCR-Validation                                                                & 4[C-E]                                  \\
        \hline
    \end{longtable}
}



% ## Example of including Figures
% > \includeimage[scale][left bottom right top]{
% >     path/to/picture.pdf/.png/.jpg
% > }{caption}{label}


% ## Fig. S1
\includeimage[0.99][{\fmleft} 1.8in {\fmright} {\fmtop}]{
    APPENDIX_CHAPTER1/figures8_supplemental1.pdf
}{
    lorem ipsum dolor sit amet consectetur adipiscing elit sed do
    eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
    veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
    commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
    esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
}{fig:S1}
\newpage

% ## Fig. S2
\includeimage[0.97][{\fmleft} {\fmbottom} {\fmright} {\fmtop}]{
    APPENDIX_CHAPTER1/figures8_supplemental2.pdf
}{
    lorem ipsum dolor sit amet consectetur adipiscing elit sed do
    eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
    veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
    commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
    esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
}{fig:S2}
\newpage

% ## Fig. S3
\includeimage[0.99][{\fmleft} {\fmbottom} {\fmright} {\fmtop}]{
    APPENDIX_CHAPTER1/figures8_supplemental3.pdf
}{
    lorem ipsum dolor sit amet consectetur adipiscing elit sed do
    eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
    veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
    commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
    esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
}{fig:S3}
\newpage

% ## Fig. S4
\includeimage[0.98][{.95\fmleft} {\fmbottom} {\fmright} {\fmtop}]{
    APPENDIX_CHAPTER1/figures8_supplemental4.pdf
}{
    lorem ipsum dolor sit amet consectetur adipiscing elit sed do
    eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
    veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
    commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
    esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
}{fig:S4}
\newpage

% ## Fig. S5
\includeimage[1][{\fmleft} {\fmbottom} {\fmright} {\fmtop}]{
    APPENDIX_CHAPTER1/figures8_supplemental5.pdf
}{
    lorem ipsum dolor sit amet consectetur adipiscing elit sed do
    eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
    veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
    commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
    esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
}{fig:S5}
\newpage


% ## Fig. S6
\includeimage[1][{\fmleft} {\fmbottom} {\fmright} {\fmtop}]{
    APPENDIX_CHAPTER1/figures8_supplemental6.pdf
}{
    lorem ipsum dolor sit amet consectetur adipiscing elit sed do
    eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
    veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
    commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
    esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
}{fig:S6}
\newpage



% ## Tab S2
{
    \footnotesize
    \newcommand{\myheader}{
        \hline
        \textbf{Regulation during disease progression} & \textbf{Gene} & \textbf{Ensemble ID} & \textbf{Progression Free / Overall Survival} & \textbf{Better Prognosis with high/low expression} & \multicolumn{2}{p{3cm}|}{\textbf{Association of expression with survival}}                    \\
        \hhline{~~~~~--}
        &               &                      &                                              &                                                    & \textbf{[p-unc]}                                                      & \textbf{[p-adj]} \\
        \hline
    }

    \begin{longtable}{|>{\bfseries}p{3cm}|>{\bfseries}p{1.9cm}|p{3cm}|p{2cm}|p{2cm}|p{1.5cm}|p{1.5cm}|}
        \caption{%
            lorem ipsum dolor sit amet consectetur adipiscing elit sed do
            eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
            veniam quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
            commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
            esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
        }\label{tab:S2}                                                                                                        \\
        \myheader
        \endfirsthead

        \multicolumn{7}{c}%
        {Appendix \thesection~\tablename\ \thetable\ -- \textit{Continued from previous page}}                                         \\
        \myheader
        \endhead

        \hline
        \multicolumn{7}{r}{\textit{Continued on next page}}                                                                            \\
        \endfoot

        \endlastfoot

        \hline

        % > These rows have only either Prog. Free or Overall Survival for one gene
        Not downregulated or overall low expression             & CCDC80   & ENSG00000091986 & Prog. Free & high & 2.04E-03 & 1.58E-02 \\
        \hhline{~------}
                                                                & CCN2     & ENSG00000118523 & Overall    & high & 2.89E-03 & 2.43E-02 \\
        \hhline{~------}
        % > This row has both Overall and Prog. Free Survival for the same gene (CCNE2)
                                                                & CCNE2    & ENSG00000118523 & Prog. Free & low  & 1.21E-02 & 4.62E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & low  & 5.34E-04 & 8.64E-03 \\
        \hhline{~------}
        % > ... more rows with only either Prog. Free or Overall Survival for one gene
                                                                & COL4A1   & ENSG00000187498 & Overall    & high & 9.47E-03 & 3.99E-02 \\
        \hhline{~------}
                                                                & COL4A2   & ENSG00000134871 & Prog. Free & high & 1.24E-02 & 4.62E-02 \\
        \hhline{~------}
        % > Continuation from the gene COL4A2
                                                                & F3       & ENSG00000117525 & Overall    & high & 9.18E-03 & 3.99E-02 \\
        \hhline{~------}
                                                                & HTRA1    & ENSG00000166033 & Prog. Free & high & 1.20E-02 & 4.62E-02 \\
        \hhline{~------}
                                                                & IGFBP7   & ENSG00000163453 & Prog. Free & low  & 9.53E-03 & 4.38E-02 \\
        \hhline{~------}
                                                                & MMP2     & ENSG00000087245 & Prog. Free & high & 2.29E-05 & 2.32E-03 \\
        \hhline{~------}
                                                                & OSMR     & ENSG00000145623 & Prog. Free & high & 5.67E-04 & 7.15E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 1.29E-02 & 4.64E-02 \\
        \hhline{~------}
                                                                & SERPINH1 & ENSG00000149257 & Prog. Free & low  & 1.83E-03 & 1.58E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & low  & 4.40E-03 & 2.61E-02 \\
        \hhline{~------}

        \hline

        % > Starting with downregulated genes
        Continuously downregulated (PC > MGUS > sMM > MM > MMR) & ACTN1    & ENSG00000072110 & Overall    & high & 7.73E-03 & 3.55E-02 \\
        \hhline{~------}
                                                                & AEBP1    & ENSG00000106624 & Prog. Free & high & 1.08E-02 & 4.62E-02 \\
        \hhline{~------}
        % > This row has both Overall and Prog. Free Survival for the same gene (AXL)
                                                                & AXL      & ENSG00000118523 & Prog. Free & high & 1.50E-03 & 1.51E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 3.64E-05 & 1.84E-03 \\
        \hhline{~------}
        % > Another row with only either Prog. Free or Overall Survival for one gene (COL1A1)
                                                                & COL1A1   & ENSG00000108821 & Prog. Free & high & 3.03E-04 & 4.37E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 5.93E-04 & 8.64E-03 \\
        \hhline{~------}
                                                                & COL3A1   & ENSG00000168542 & Overall    & high & 1.08E-02 & 4.29E-02 \\
        \hhline{~------}
                                                                & COL6A1   & ENSG00000142156 & Prog. Free & high & 1.20E-02 & 4.62E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 1.10E-02 & 4.29E-02 \\
        \hhline{~------}
                                                                & CXCL12   & ENSG00000107562 & Prog. Free & high & 1.16E-04 & 2.93E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 6.48E-04 & 8.64E-03 \\
        \hhline{~------}
                                                                & CYP1B1   & ENSG00000138061 & Prog. Free & high & 8.64E-03 & 4.17E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 6.84E-04 & 8.64E-03 \\
        \hhline{~------}
                                                                & DCN      & ENSG00000011465 & Prog. Free & high & 4.83E-03 & 3.05E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 2.47E-04 & 8.33E-03 \\
        \hhline{~------}
                                                                & FBLN1    & ENSG00000077942 & Prog. Free & high & 2.68E-03 & 1.93E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 3.73E-03 & 2.61E-02 \\
        \hhline{~------}
                                                                & GNB3     & ENSG00000111664 & Prog. Free & high & 3.75E-03 & 2.52E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 5.73E-03 & 3.05E-02 \\
        \hhline{~------}
                                                                & IGFBP4   & ENSG00000141753 & Prog. Free & high & 8.68E-03 & 4.17E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 7.09E-03 & 3.41E-02 \\
        \hhline{~------}
                                                                & ITGAX    & ENSG00000140678 & Prog. Free & high & 6.72E-03 & 3.60E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 3.12E-03 & 2.43E-02 \\
        \hhline{~------}
                                                                & LAMB2    & ENSG00000172037 & Overall    & high & 1.35E-03 & 1.39E-02 \\
        \hhline{~------}
                                                                & LRP1     & ENSG00000123384 & Prog. Free & high & 6.46E-03 & 3.60E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 4.34E-04 & 8.64E-03 \\
        \hhline{~------}
                                                                & LTBP2    & ENSG00000119681 & Prog. Free & high & 9.03E-05 & 2.93E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 1.17E-02 & 4.36E-02 \\
        \hhline{~------}
                                                                & MAP3K8   & ENSG00000107968 & Prog. Free & high & 9.58E-04 & 1.08E-02 \\
        \hhline{~------}
                                                                & MFAP5    & ENSG00000197614 & Prog. Free & high & 2.43E-04 & 4.09E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 4.27E-03 & 2.61E-02 \\
        \hhline{~------}
                                                                & MMP14    & ENSG00000157227 & Prog. Free & high & 6.93E-05 & 2.93E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 6.69E-03 & 3.38E-02 \\
        \hhline{~------}
                                                                & MYL9     & ENSG00000101335 & Prog. Free & high & 1.46E-04 & 2.95E-03 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 1.56E-05 & 1.57E-03 \\
        \hhline{~------}
                                                                & NRP1     & ENSG00000099250 & Prog. Free & high & 1.89E-03 & 1.58E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 2.21E-03 & 2.03E-02 \\
        \hhline{~------}
                                                                & TGFBI    & ENSG00000120708 & Overall    & high & 4.30E-03 & 2.61E-02 \\
        \hhline{~------}
                                                                & TNC      & ENSG00000041982 & Prog. Free & high & 1.28E-02 & 4.62E-02 \\
        \hhline{~~~----}
                                                                &          &                 & Overall    & high & 4.75E-03 & 2.67E-02 \\
        \hhline{~------}
                                                                & TPM1     & ENSG00000140416 & Overall    & high & 1.37E-03 & 1.39E-02 \\
        \hhline{~------}
                                                                & TUBA1A   & ENSG00000167552 & Prog. Free & low  & 6.78E-03 & 3.60E-02 \\
        \hhline{~------}





        % > ... rest of rows for downregulated genes...

        \hline
    \end{longtable}
}


\newpage



% == Supplementary Materials and Methods ===============================
\subsection{Materials \& Methods}
\label{subapdx:materialsmethods}
Lorem ipsum dolor

\newpage




%%%%%%% Test References
V-Well is described in \refapdx{apdx:supplemental}{fig:S1}

V-Well is described in \refapdx{apdx:supplemental}{fig:S1}, \ref{fig:S2}

% Image cytometry is described in \autoref{subapdx:sup_figtabs} \autoref{fig:S2}

Full analysis is shown in \refapdx{subapdx:example_analysis}

% Referenzen als Fu√ünoten ab hier?